A randomized, Open-label, Single Dose, Two Treatment, Three-Period, Three-Sequence, Partial Replicate, Crossover, Multicentre, Bioequivalence Study of Capecitabine 500 mg Tablets (Manufactured by SP Accure Labs Pvt. Ltd., India) with XelodaÂ® (Capecitabine 500 mg Tablets Distributed Roche Registration GmbH) in Adult Cancer Patients Under Fed Condition.

SP Accure Labs Pvt Ltd0 个研究点目标入组 33 人开始时间: 待定最近更新: 2023年3月6日

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 33

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1.Males or non-pregnant or non-lactating females of age between 18 to 65 years (both inclusive).
•2.Patients in whom capecitabine therapy is indicated
•i.Dukesâ?? C colon cancer: Single agent as adjuvant therapy; or
•ii.Metastatic colorectal cancer: First line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred; or
•iii.Metastatic Breast Cancer: As monotherapy in patients resistant to both paclitaxel and an anthracycline containing regimen.
•3.Patients already receiving a stable twice-daily dosing regimen of capecitabine (i.e. 1250 mg/m2, twice daily, equivalent to 2500 mg/m2 total daily dose, for two-weeks followed by a one-week rest period given as three-week cycles).
•4.Patients with Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
•5.Patients with life expectancy of at least 3 months.
•6.Adequate cardiac function [left ventricular ejection fraction (LVEF) >= 50%].
•7.Patient with adequate ÂBone marrow (ANC >= 1500/mm3, Platelet count >= 100,000/mm3, Hemoglobin >= 9.0 g/dL);ÂRenal (Serum Creatinine <= 1.5 times ULN and creatinine clearance >= 51 to 80 mL/min [Cockroft and Gault]) and Hepatic function (Bilirubin <= 1.5 times ULN, ALT/AST <= 3 times ULN (<= 5 x ULN if liver metastases present)).
•8.Patients should be non-smokers.
•9.Patient willing and able to give written informed consent for participation in the study and comply with the study protocol.
•10.No persistent clinically significant toxicities from prior medications at screening.
•11.Females of child-bearing potential must agree to use an acceptable method of birth control such as sexual abstinence or at least reliable modes of contraception from screening until 3 months after last dose of study drug.
•[Note: Use of hormonal contraception (pills/hormonal intrauterine device etc,) is not allowed].
•OR Post-menopausal females defined as at least 12 consecutive months with no menses without an alternative medical cause.
•OR Surgically sterilized females with documented evidence of hysterectomy/bilateral salpingectomy/bilateral oophorectomy.
•12.Male patient must agree to use an acceptable method of birth control such as sexual abstinence or barrier method of contraception (i.e. condom) from screening until 3 months after last dose of study drug. Subject agrees to accept the risk that pregnancy in female partner could still result despite using birth control devices.
•13.Cancer patients should preferably be on monotherapy. However, cancer patients receiving concomitant drug(s) are allowed to participate, provided:
•Â-The concomitant medication is the same for all the study period and clearly documented.
•Â-Patients do not require any change in their concurrent medications during the study period.

排除标准

•1.Patients with known hypersensitivity to capecitabie or to any of its components of formulation or 5-fluorouracil.
•2.Patients with known DPD (Dihydro pyrimidine Dehydrogenase) deficiency.
•3.Prior unanticipated severe reaction to Capecitabine or metabolites and to fluoropyrimidine therapy.
•4.Patients with a prior history of coronary artery disease.
•5.Patients who are on oral-coumarin derivative anticoagulants such as warfarin or phenprocoumon at the time of screening or anticipated use of these drugs during the study period. [If the subject was on any of these drugs before screening, a wash out period of at least 5 half-lives must have elapsed since the last dose of such drug.]
•6.Patients receiving concomitant therapy of Phenytoin, Leucovorin, and CYP2C9 substrates at the time of screening or anticipated use of these drugs during the study period. [If the subject was on any of these drugs before screening, a wash out period of at least 5 half-lives must have elapsed since the last dose of such drug.] Presence of active infections.
•7.Patients with known brain metastasis.
•8.Pre-existing motor or sensory neurotoxicity of severity >= 2 by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) criteria.
•9.Use of any recreational drugs or history of drug addiction.
•10.Have a history of alcohol or drug-dependence as per DSM-IV criteria during the 6-month period immediately prior to Screening.
•11.Consumption of grapefruit, grapefruit-like or grapefruit containing products within 7 days prior to study drug administration.
•12.Use of enzyme modifying drugs within 30 days prior to study drug administration. They can be allowed depending on Principal Investigatorâ??s discretion if they are kept constant in the last 30 days and are expected to remain constant during the study period.
•13.Major surgery to the gastrointestinal tract, liver or kidney within 3 months prior to study entry which may affect the pharmacokinetics of capecitabine.
•14.History of difficulty in swallowing, or any gastrointestinal disease e.g. ulcerative colitis, ulcerative stomatitis, malabsorption syndrome and/or lack of physical integrity of the upper intestinal tract which could affect drug absorption.
•15.History or presence of cardiac disease including myocardial infarction, unstable angina, coronary artery disease, heart failure, dysrhythmias, cardiomyopathy, significant pericardial disease or any other cardiac illness that could affect patient safety.
•16. Electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
•17.History or evidence of uncontrolled coagulopathy.
•18.Patients with severe hepatic or renal impairment.
•19.Patient having abnormal serum calcium level at screening visit which as judged by Investigator could lead to safety risk to the patient upon participation in the trial or could interfere with the conduct of the trial.
•20.Patients who have had experienced a severe mucocutaneous reaction during prior capecitabine treatment.
•21.History of difficulty with donating blood or difficulty in accessibility of veins or intolerance to venepuncture or patients who have bled more than 300 mL in the past 3 months.
•22.Participation in any clinical trial of investigational drugs or devices in the past 3 months.
•23.Any significant disease or condition of haemopoie

研究者

发起方

SP Accure Labs Pvt Ltd

相似试验

尚未招募

4 期

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Lercanidipine 20 mg Film-coated Tablets and Reference Product (ZANIDIP) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai Volunteers

TCTR20230120003International Bio Service48

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Dabigatran Etexilate Capsules 150 mg and Reference Product (Pradaxa) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study Healthy Thai VolunteersDabigatran etexilate 150 mg Capsules in Healthy Thai Volunteers

TCTR20230427002International Bio Service Co.,Ltd48

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Racecadotril 100 mg Capsules and Reference Product (HIDRASEC) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai Volunteers

TCTR20240604001International Bio Service44

已完成

不适用

A Study of Methotrexate Tablets 2.5 mg in Adult Patients with Inflammatory Disorder of many joints and/or Patches of Abnormal Ski

CTRI/2018/11/016245Intas Pharmaceuticals Limited42

已完成

不适用

To compare bioavailibilityof Capecitabine 500 mg tablets(manufactured by Reliance Life Sciences Pvt.Ltd., India) with XelodaÂ® (Capecitabine 500 mgtablets distributed by Genentech USA, Inc.) inadult cancer patients under fed condition.

CTRI/2017/09/009930Reliance Life sciences Pvt Ltd84